FDC LTD. - 531599 - Outcome Of Board Meeting Held On November 11, 2021
Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Unaudited Financial Results for the quarter and half year ended September 30, 2021 along with the Limited Review Report dated November 11, 2021, as issued by the Statutory Auditors of the Company thereon. FDC LTD. - 531599 - Board Meeting Outcome for Outcome Of Board Meeting Held On November 11, 2021.
Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Unaudited Financial Results for the quarter and half year ended September 30, 2021 along with the Limited Review Report dated November 11, 2021, as issued by the Statutory Auditors of the Company thereon. FDC LTD. - 531599 - Receipt Of GMP (Good Manufacturing Practice) Certificate From UK MHRA (Medicine And Healthcare Products Regulatory Agency).
Dear Sir/ Madam, This is to inform you that, today the Company has received Good Manufacturing Practice (GMP) certificate. It continues with its approved status from UK MHRA (Medicines and Healthcare Products Regulatory Agency), for the Ophthalmic facility located at Waluj, Aurangabad, Maharashtra, based on the recent GMP inspection held remotely between 06th to 09th September, 2021. Kindly take the above on record. Thanking you, Yours truly, For FDC LIMITED Sd/- Varsharani Katre Company Secretary F-8948 FDC LTD. - 531599 - Board Meeting Intimation for Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
FDC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2021 ,inter alia, to consider and approve to consider and approve the Unaudited Financial Results and Limited Review Report of the Company for the quarter and half year ended September 30, 2021. FDC Ltd - 531599 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Submission of Information pursuant to the Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding Loss of shares certificate / Issue of duplicate share certificate.
Glenmark launches unique fixed dose combination drug for diabetes
The Mumbai based drug firm said it has introduced fixed dose combination (FDC) of its novel, patent protected Sodium Glucose Co-Transporter Inhibitor (SGLT2i) Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) Vildagliptin, with Metformin. FDC LTD. - 531599 - Shareholding for the Period Ended September 30, 2021
FDC Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here FDC LTD. - 531599 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1450 Name of the Signatory :- Varsharani KatreDesignation :- Company Secretary and Compliance Officer FDC LTD. - 531599 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate in terms of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 ("said regulations") on behalf of FDC Limited (lithe Company") for the quarter ended on September 30, 2021. FDC LTD. - 531599 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
FDC Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here